AusperBio
PrivateLast Round
Series C
Aug 27, 2026
Total Funding Raised
$356.7M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
AusperBio is a biopharmaceutical company that develops targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B and other liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AusperBio Comparables
Compare AusperBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mirum Pharmaceuticals | 84% | |
| Arbutus Biopharma Corp | 81% | |
| Ionis Pharmaceuticals, Inc. | 79% |
AusperBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 27, 2026 | ||||
| Series B Extension | Sep 21, 2025 | ||||
| Series B Extension | May 28, 2025 | ||||
| Series B | Dec 26, 2024 | ||||
| Series A | Jul 14, 2024 | ||||
Seed | Nov 7, 2023 |
AusperBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Series B Extension, Series B |
| RA Capital Management | Series C |
| Genesis Capital | Series B Extension |
| YuanBio Venture Capital | Series B Extension, Series B, Series A, Series C |
| Genesis Capital | Series B Extension, Series A |
| Sherpa Capital | Series B Extension, Series B, Series C |
| Sherpa Capital | Series B Extension, Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
$120M round with participation from CDH Investments and Hankang Capital.
- Jul 26, 2026
Monthly visitors increased 168% MoM.
Recent news
Latest coverage and updates
- is_developingAug 28, 2026
AusperBio Therapeutics, Inc. is developing combination regimens that pair multiple therapeutic mechanisms.
AusperBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AusperBio's valuation, stock price, and market status.
Is AusperBio a public or private company?
AusperBio is a private company.
What is the current stock price of AusperBio?
AusperBio is a private company with no public stock price. No recent secondary market data is available.
How much is AusperBio worth (valuation)?
Valuation information for AusperBio is not publicly available.
Can I buy AusperBio stock?
AusperBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AusperBio's last funding round?
AusperBio's most recent funding round was Series B Extension on September 21, 2025.
Who are the main investors in AusperBio?
Key investors in AusperBio include Hankang Capital, Qiming Venture Partners.
Will AusperBio IPO soon?
No public IPO plans have been announced for AusperBio.
How can I track AusperBio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AusperBio's secondary market activity and sign up for updates.